The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: Are patients from South-East Asia eligible?

European Respiratory Journal

Volumn 50, Issue 2, 2017, Pages

  Chee, Cynthia B E ^a   KhinMar, Kyi Win ^a   Sng, Li H ^b   Jureen, Roland ^c   Cutter, Jeffery ^d   Lee, Vernon J M ^d   Wang, Yee Tang ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d MINISTRY OF HEALTH   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

BANGLADESH; CHINA; HUMAN; INDIA; INDONESIA; LETTER; MALAYSIA; MULTIDRUG RESISTANT TUBERCULOSIS; MYANMAR; PHILIPPINES; PRIORITY JOURNAL; REGISTER; SINGAPORE; VIET NAM; WORLD HEALTH ORGANIZATION; DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MYCOBACTERIUM TUBERCULOSIS; SOUTHEAST ASIA; TREATMENT OUTCOME;

ANTITUBERCULAR AGENTS; ASIA, SOUTHEASTERN; DRUG ADMINISTRATION SCHEDULE; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SINGAPORE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85027835008     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00753-2017     Document Type: Letter

References (15)

1. Global tuberculosis report 2016. Geneva, World Health Organization, 2016. http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1
2. Van Deun A, Maug AKJ, Salim MAH, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
3. Kuaban C, Noeske J, Rieder HL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517-524.
4. Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardized short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188-1194.
5. Falzon D, Schunemann H, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
6. Varaine F, Guglielmetti L, Huerga H, et al. Eligibility for the shorter multidrug resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations. Am J Respir Crit Care Med 2016; 194: 1028-1029.
7. Balabanova Y, Fiebig L, Ignatyeva O, et al. Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule? Thorax 2017; in press [https://doi.org/10.1136/thoraxjnl-2016-209841].
8. Lange C, Duarte R, Frechet-Jachym M, et al. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe. Am J Respir Crit Care Med 2016; 194: 1029-1031.
9. van der Werf MJ, Hollo V, Kodmon C, et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union. Eur Respir J 2017; 49: 1601992.
10. Sotgiu G, Tiberi S, D'Ambrosio L, et al. Faster for less: the new shorter regimen for multidrug-resistant tuberculosis. Eur Respir J 2016; 48: 1503-1507.
11. Jarvaid A, Ahmad N, Khan AH, et al. Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country. Eur Respir J 2017; 49: 1601967.
12. Dalcolmo M, Gayoso R, Sotgiu G, et al. Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015. Eur Respir J 2017; 49: 1602309.
13. Zignol M, Dean AS, Alikhanova N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis 2016; 16: 1185-1192.
14. Communicable diseases surveillance in Singapore 2015. Singapore, Singapore Ministry of Health, 2016. www.moh.gov.sg/content/dam/moh-web/Publications/Reports/2016/Full%20Version.pdf
15. Yakrus MA, Driscol J, McAlister A, et al. Molecular and growth-based drug susceptibility testing of Mycobacterium tuberculosis complex for ethambutol resistance in the United States. Tuberc Res Treat 2016; 2016: 3404860.